AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03775564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual
Study NCT04474314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687
Study NCT00525668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epigallocatechin-gallate (Sunphenon)
Description: 200 mg twice daily, after 3 months 400 mg twice daily
Study NCT02539576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC FDC tablet
Description: ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.
Study NCT03443206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anonymous social support
Description: Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
Study NCT00525668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
Study NCT04324801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeostatic plasticity induction using transcranial direct current stimulation
Description: Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
Study NCT03443206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: educational materials related to mental health
Study NCT03443206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: educational materials related to mental health
Study NCT03443206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online resources
Description: links to online mental health resources
Study NCT01771146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRINOX Regimen
Description: 6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
Study NCT03181854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone coaching
Description: Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
Study NCT03181854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation with PCT doctor
Description: Consultation with PCT physician every 3 weeks.
Study NCT00142870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: 150 mg, twice a day
Study NCT02635516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Phototherapy
Description: The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized.
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 low dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 medium dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR277 high dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril low dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril medium dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril high dose
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BIBR277
Study NCT02177448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching enalapril
Study NCT03031808 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine spray (2%)
Description: Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
Study NCT03031808 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Muscle Relaxant (Rocuronium)
Description: After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
Study NCT03031808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Muscle relaxant, no Lidocaine
Description: This group get general anesthesia without Rocuronium or Lidocaine
Study NCT03887000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
Study NCT03887000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
Study NCT03149107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
Study NCT03149107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
Study NCT03149107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
Study NCT03149107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPPI (Integrated Preventive Psychological Intervention)
Description: IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
Study NCT03149107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSM (Psychological stress management)
Description: PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
Study NCT03149107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PSM (Psychological stress management)
Description: PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
Study NCT01983527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrographic distention
Description: Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
Study NCT01983527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrographic distention
Description: Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
Study NCT01983527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid Depo Medrol
Description: Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
Study NCT01983527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid Depo Medrol
Description: Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, (TBD), once daily, 2 days
Study NCT00380601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks
Study NCT00582842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
Study NCT00582842 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey instruments using Web-Based Data Collection System (WBDC) survey content
Description: The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
Study NCT03342547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal biopsy
Description: Two duodenal biopsy samples will be collected from each participant
Study NCT03342547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva
Description: Saliva (1-2 mL) will be collected from each participant for secretor status testing
Study NCT02687984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Study NCT02687984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBP-7000
Description: A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Study NCT03419689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour tissue collection
Description: Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression
Study NCT03419689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression
Study NCT03419689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites Collection
Description: Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression
Study NCT03419689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Collection
Description: Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
Study NCT03659929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine Sulfate
Description: active experimental AR19
Study NCT03659929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03333265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg Berberine hydrochloride
Description: patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
Study NCT04474314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of once daily Placebo
Study NCT03333265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg Berberine hydrochloride
Description: patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
Study NCT03333265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
Study NCT02813941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current GRADE SoF table
Description: The current GRADE SoF table will be the common comparator for the other two SoF tables
Study NCT02813941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative GRADE SoF table
Description: The alternative GRADE SoF table format will be developed from a user-testing survey.
Study NCT02813941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EPC SoF table
Description: For the EPC SoF table, the investigators will use one of their format which was recently published
Study NCT01804972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal and written information
Description: Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
Study NCT01804972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal and electronic information
Description: Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
Study NCT03762694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture (EA) and Auricular Acupuncture (AA)
Study NCT01911897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: Implant that is placed in the carotid sinus to control hypertension.
Study NCT03333135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field therapy (PEMF)
Description: PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Study NCT03333135 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulsed Electromagnetic Field Sham therapy
Description: PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Study NCT00619060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Myristyl Nicotinate Cream
Description: Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
Study NCT00619060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants apply topical placebo to one forearm once daily for 4 weeks.
Study NCT02716545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon assisted enteroscopy
Description: Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
Study NCT05304312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kegel Exercises guidebook
Description: The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
Study NCT03544307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taekwondo training
Description: Exercise group
Study NCT00436592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo™ Catheter
Description: 45 minute Treatment
Study NCT00903331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-064992 (macitentan)
Description: ACT-064992 (macitentan) tablet, 10 mg, once daily
Study NCT00903331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo, once daily
Study NCT03525132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry + Optic Adaptative Camera
Description: Fluxometry measure while subject is sitting in front of the optic adaptative camera
Study NCT04003493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and oral health intervention
Description: The interventions included individualised nutrition and oral health care.
Study NCT01340131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Study NCT01340131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy
Description: Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily
Study NCT03340974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
Study NCT03340974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
Study NCT03340974 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy (SBRT) 50 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
Study NCT03340974 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Radiation Therapy (SBRT) 50 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
Study NCT03340974 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy (SBRT) 55 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
Study NCT03340974 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Radiation Therapy (SBRT) 55 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
Study NCT03742505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
Study NCT03742505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
Study NCT01707017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Study NCT03759938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant (DOAC)
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
Study NCT03759938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct oral anticoagulant (DOAC)
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
Study NCT03885687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with Music
Description: The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
Study NCT03885687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
Study NCT03300583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Focus group discussion led by the PI and facilitated by another researcher.
Study NCT03300583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semi-structured interviews
Description: 1:1 semi-structured interviews led by the PI